Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Development and clinical indications of PARP inhibitors

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 3936

Dr Mark O'Connor - AstraZeneca, Cambridge, UK

Dr O’Connor speaks with ecancer at AACR 2018 about the development and application of PARP inhibitors, such as olaparib, for ovarian and breast cancers.

He describes his research in treatment tolerability and the overlap of efficacy with observed PARP trapping.

For more on PARP inhibitors watch our interview with Dr Elisabetta Leo here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation